Class II — Potential Health Hazard

Potential health hazard — use of or exposure to this product may cause temporary or medically reversible adverse health consequences.

Hylenex recombinant (hyaluronidase) injection Recalled by Mckesson Medical-Surgical Inc. Corporate Office Due to cGMP Deviations: Temperature excursion

Date: September 11, 2024
Company: Mckesson Medical-Surgical Inc. Corporate Office
Status: Terminated
Source: FDA (Drug)

What You Should Do

Stop using this product immediately. Do not consume, use, or distribute it.

Return the product to the place of purchase for a full refund. If you have questions, contact Mckesson Medical-Surgical Inc. Corporate Office directly.

Affected Products

Hylenex recombinant (hyaluronidase) injection, 150 USP units/mL, 4x1 mL Single Dose Vials, Rx only, Manufactured for and marketed by Halozyme, Inc., 12390 El Camino Real San Diego California 92130, Distributed by Antares Pharma, Inc., Ewing, NJ NDC 18657-117-04

Quantity: 5 cartons/20 units each carton

Why Was This Recalled?

cGMP Deviations: Temperature excursion

Where Was This Sold?

Virgina

About Mckesson Medical-Surgical Inc. Corporate Office

Mckesson Medical-Surgical Inc. Corporate Office has 276 total recalls tracked by RecallDetector.

Related Recalls

Data sourced from the FDA (Drug). Last updated March 26, 2026. View original report